TH126338A - - Google Patents
Info
- Publication number
- TH126338A TH126338A TH901003267A TH0901003267A TH126338A TH 126338 A TH126338 A TH 126338A TH 901003267 A TH901003267 A TH 901003267A TH 0901003267 A TH0901003267 A TH 0901003267A TH 126338 A TH126338 A TH 126338A
- Authority
- TH
- Thailand
- Prior art keywords
- substances
- signal transduction
- spirocyclic
- salts
- formula
- Prior art date
Links
- 229940079593 drug Drugs 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract 7
- 150000003839 salts Chemical class 0.000 abstract 4
- 230000019491 signal transduction Effects 0.000 abstract 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 abstract 2
- 208000019693 Lung disease Diseases 0.000 abstract 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 abstract 2
- 229960000367 inositol Drugs 0.000 abstract 2
- 210000004072 lung Anatomy 0.000 abstract 2
- 150000007522 mineralic acids Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000007524 organic acids Chemical class 0.000 abstract 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 208000023504 respiratory system disease Diseases 0.000 abstract 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 230000001173 tumoral effect Effects 0.000 abstract 2
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TH126338A true TH126338A (sr) | 2013-08-19 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mishra et al. | The development of Hsp90β-selective inhibitors to overcome detriments associated with pan-Hsp90 inhibition | |
| Aronov et al. | Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors | |
| Kraege et al. | The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2) | |
| EA201001241A1 (ru) | Спирогетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения | |
| EA200901608A1 (ru) | Производные хинаксолина в качестве ингибиторов тирозинкиназной активности киназ janus | |
| CY1114092T1 (el) | Σπειρο υποκατεστημενες ενωσεις ως αναστολεις αγγειογενεσης | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| MX2009011964A (es) | Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico. | |
| EA201300872A1 (ru) | Дималеат 9-[4-(3-хлор-2-фторфениламино)-7-метоксихиназолин-6-илокси]-1,4-диазаспиро[5.5]ундекан-5-она, его применение в качестве лекарственного средства и его получение | |
| Osman et al. | Design, synthesis, anticancer, and antibacterial evaluation of some quinazolinone‐based derivatives as DHFR inhibitors | |
| UY26902A1 (es) | Heterocíclicos bicíclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparación | |
| KR20130130753A (ko) | 퀴나졸린 카르복사미드 아제티딘 | |
| UY28191A1 (es) | Heterociclos biciclicos, medicamentos que contienen estos compuestos, su utilización y procedimientos para su preparación. | |
| TW200730508A (en) | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | |
| Marques et al. | Targeting vascular endothelial growth factor receptor 2 (VEGFR-2): Latest insights on synthetic strategies | |
| ECSP099562A (es) | Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su utilización y procedimientos para su preparación | |
| El-Damasy et al. | ABL kinase inhibitory and antiproliferative activity of novel picolinamide based benzothiazoles | |
| RU2017112299A (ru) | Способ получения ароматического гетероциклического соединения, применяемого в качестве селективного ингибитора киназы jak1, и применение ароматического гетероциклического соединения | |
| Gryshchenko et al. | Design, synthesis and biological evaluation of 5-amino-4-(1H-benzoimidazol-2-yl)-phenyl-1, 2-dihydro-pyrrol-3-ones as inhibitors of protein kinase FGFR1 | |
| Modh et al. | Synthesis and Evaluation of Novel 4‐Substituted Styryl Quinazolines as Potential Antimicrobial Agents | |
| Giordanetto et al. | Discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing Phosphoinositide 3-kinase (PI3K) p110β isoform inhibitors through structure-based fragment optimisation | |
| DE602007001952D1 (de) | 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren | |
| ECSP045330A (es) | Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su utilización y procedimiento para su preparación | |
| Houghton et al. | Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program | |
| DE602006017111D1 (de) | Chinazolinon-derivate als vanilloid-antagonisten |